title: Going past the data for temozolomide.
abstract: The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.
authors.affiliation: Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 840 S Wood St Rm 839, M/C 713, Chicago, IL 60612, USA. jvillano@uic.edu
authors.forename: J Lee
authors.initials: JL
authors.lastname: Villano
authors.forename: Nathalie
authors.initials: N
authors.lastname: Letarte
authors.forename: Linda R
authors.initials: LR
authors.lastname: Bressler
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide